|
Volumn 134, Issue 8, 2016, Pages 571-573
|
Randomized trials to evaluate cardiovascular safety of antihyperglycemic medications
|
Author keywords
diabetes complications; diabetes mellitus; empagliflozin; liraglutide; randomized controlled trials
|
Indexed keywords
ALEGLITAZAR;
ANTIDIABETIC AGENT;
ANTINEOPLASTIC AGENT;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
EMPAGLIFLOZIN;
GLUCOSE;
LIRAGLUTIDE;
PIOGLITAZONE;
PLACEBO;
SEMAGLUTIDE;
ACUTE HEART INFARCTION;
ANTIDIABETIC ACTIVITY;
ARTICLE;
BLINDNESS;
BLOOD GLUCOSE MONITORING;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CEREBROVASCULAR ACCIDENT;
CLINICAL EVALUATION;
DIABETES MELLITUS;
DIALYSIS;
DISEASE COURSE;
DRUG EFFICACY;
DRUG SAFETY;
EUROPEAN MEDICINES AGENCY;
FOOD AND DRUG ADMINISTRATION;
GLYCEMIC CONTROL;
HEALTH CARE COST;
HEART FAILURE;
HEART INFARCTION;
HUMAN;
HYPERGLYCEMIA;
KIDNEY FAILURE;
MANAGED CARE;
NEOPLASM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK ASSESSMENT;
RISK FACTOR;
STENT THROMBOSIS;
SURVIVOR;
BLOOD;
CHEMICALLY INDUCED;
DIABETES MELLITUS, TYPE 2;
ECONOMICS;
GLYCEMIC INDEX;
PROCEDURES;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
GLYCEMIC INDEX;
HUMANS;
HYPOGLYCEMIC AGENTS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
EID: 84983667048
PISSN: 00097322
EISSN: 15244539
Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.116.021914 Document Type: Article |
Times cited : (13)
|
References (6)
|